来那度胺治疗不适合移植的多发性骨髓瘤患者同时性与第二原发恶性肿瘤的风险
本研究基于法国人群癌症登记数据,纳入2018年起连续360例不适合移植的新诊断多发性骨髓瘤患者,其中174例接受来那度胺治疗,中位随访36个月。结果显示同时性恶性肿瘤风险显著升高(SIR 8.20),而接受来那度胺且未暴露于传统化疗者的第二原发恶性肿瘤风险与一般人群相比似乎未升高(SIR 1.28)。
要点
- 诊断前4个月内诊断的额外恶性肿瘤定义为同时性恶性肿瘤,超过4个月者为第二原发恶性肿瘤。
- 360例患者中35例(9.7%)发生额外恶性肿瘤,SIR为2.17。
- 来那度胺治疗者第二原发恶性肿瘤SIR为1.28,3年累积发生率为3.6%。
核心结论
- 不适合移植的新诊断多发性骨髓瘤患者被同时诊断同时性恶性肿瘤的风险高,可能与时诊断时的检查有关;接受来那度胺且从未暴露于传统化疗的患者,第二原发恶性肿瘤风险与一般人群相比似乎未升高。
研究设计与样本
- 研究为基于人群的高分辨率癌症登记研究,纳入期自2018年开始,因法国来那度胺报销而设定。
- 共识别360例连续的不适合移植的新诊断多发性骨髓瘤患者,其中174例接受来那度胺治疗。
- 采用人年法与间接标准化分析,中位随访36个月,主要终点为同时性与第二原发恶性肿瘤,登记数据完整性好、无报告偏倚。
主要发现
- 全部360例中,35例(9.7%)发生额外恶性肿瘤,SIR为2.17;16例(4.4%)发生同时性恶性肿瘤,SIR为8.20;19例(6.4%)发生第二原发恶性肿瘤,SIR为1.15。
- 接受来那度胺治疗的患者中,12例(6.9%)发生第二原发恶性肿瘤,SIR为1.28,3年累积发生率为3.6%。
- 额外恶性肿瘤定义为多发性骨髓瘤诊断后4个月及以内诊断者为同时性恶性肿瘤,超过4个月者为第二原发恶性肿瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An increased risk of second primary malignancies (SPMs) was reported for transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) exposed to lenalidomide (Len), with the caveats that Len was often coexposed to alkylating agents and the studies did not exclude synchronous malignancies (SyMs). We aimed to evaluate the respective SyM over SPM risks in TI patients with NDMM treated with Len as frontline therapy. We conducted a high-resolution, population-based cancer registry study, which allowed completeness of the primary end point (SyMs and SPMs) without reporting bias, and provided a cohort more representative of real-life than those in clinical trials. The inclusion period started recently (2018) due to the reimbursement of Len in France. Additional malignancies (AdMs) diagnosed ≤4 months of MM diagnosis were defined as SyMs; those diagnosed >4 months were considered SPMs. The person-year approach was used with an indirect standardization. With a median follow-up of 36 months, 360 consecutive TI patients with NDMM were identified, including 174 treated with Len. In total, 35 patients (9.7%) had an AdM (standardized incidence ratio [SIR], 2.17), 16 (4.4%) had an SyM (SIR, 8.20), and 19 (6.4%) had an SPM (SIR, 1.15). Among patients treated with Len, 12 (6.9%) had an SPM (SIR, 1.28), and cumulative incidence was 3.6% at 3 years. TI patients with NDMM have a high risk of being codiagnosed with an SyM possibly explained by examinations performed at the time of MM diagnosis. In contrast, patients treated with Len who were never exposed to conventional chemotherapy did not seem to have an increased risk of SPM compared with the general population.
引用
- Systchenko T, Nsiala L, Bobin A, et al. Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide. Blood Adv. 2025. PMID: 40864187. doi:10.1182/bloodadvances.2025016625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。